EMA Withdrawn: PreHevbri (hepatitis B surface antigen) — VBI Vaccines B.V.

View source ↗

Summary

The EMA has withdrawn the marketing authorization for PreHevbri (hepatitis B surface antigen) from VBI Vaccines B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• PreHevbri (hepatitis B surface antigen)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis B. MAH: VBI Vaccines B.V.. Decision date: 25/11/2024